Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
docetaxel + plinabulin
- Development stage
- Phase 3
- Lead developer
- BeyondSpring
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
Docetaxel + plinabulin is a combination therapy under investigation primarily for the treatment of non-small cell lung cancer (NSCLC), particularly in patients with EGFR wild-type tumors who have received prior treatments. Docetaxel is a well-established microtubule-stabilizing chemotherapeutic agent, while plinabulin is a novel, investigational small molecule that acts as an immunomodulating microtubule-destabilizing agent. Plinabulin binds to the colchicine-binding site on β-tubulin, disrupting tumor vasculature and promoting dendritic cell maturation and T-cell activation via GEF-H1 activation. This combination has demonstrated improved overall survival and reduced incidence of severe neutropenia compared to docetaxel alone in Phase 3 clinical trials. The regimen is being developed by BeyondSpring Pharmaceuticals[1][2][3][4][5][6].
- Other names
- plinabulin + docetaxel
02
Targets
ARHGEF2 (Guanine nucleotide exchange factor H1)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on docetaxel + plinabulin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on docetaxel + plinabulin.